Thomas A. Waldmann
Thomas A. Waldmann | |
|---|---|
| Born | September 21, 1930 |
| Died | September 25, 2021 |
| Nationality | American |
| Alma mater | Harvard Medical School |
| Known for | Interleukin-2 research, Adult T-cell leukemia/lymphoma |
| Awards | Lasker-DeBakey Clinical Medical Research Award |
| Scientific career | |
| Fields | Immunology, Oncology |
| Institutions | National Institutes of Health |
Thomas A. Waldmann (September 21, 1930 – September 25, 2021) was an American immunologist and oncologist renowned for his pioneering research in the field of interleukin-2 (IL-2) and its receptor, as well as his work on adult T-cell leukemia/lymphoma (ATLL).
Early Life and Education[edit | edit source]
Thomas A. Waldmann was born in New York City, New York. He pursued his undergraduate studies at Princeton University and later attended Harvard Medical School, where he earned his medical degree.
Career[edit | edit source]
Waldmann spent the majority of his career at the National Institutes of Health (NIH), where he made significant contributions to the understanding of the immune system and cancer. His research focused on the role of cytokines in immune regulation and the development of monoclonal antibodies for therapeutic use.
Research Contributions[edit | edit source]
Interleukin-2 and Its Receptor[edit | edit source]
Waldmann's work on interleukin-2 (IL-2) and its receptor was groundbreaking. He elucidated the structure and function of the IL-2 receptor, which has been crucial in the development of immunotherapy for various cancers and autoimmune diseases.
Adult T-cell Leukemia/Lymphoma[edit | edit source]
Waldmann also made significant strides in understanding and treating adult T-cell leukemia/lymphoma (ATLL), a rare and aggressive form of cancer. His research led to the development of targeted therapies that have improved the prognosis for patients with this disease.
Awards and Honors[edit | edit source]
Throughout his career, Waldmann received numerous awards and honors, including the prestigious Lasker-DeBakey Clinical Medical Research Award for his contributions to medical science.
Legacy[edit | edit source]
Thomas A. Waldmann's work has had a lasting impact on the fields of immunology and oncology. His research has paved the way for new treatments and therapies that continue to benefit patients worldwide.
See Also[edit | edit source]
- Interleukin-2
- Adult T-cell leukemia/lymphoma
- National Institutes of Health
- Immunotherapy
- Monoclonal antibodies
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
